

Article

# Biocatalytic Synthesis of Pikromycin, Methymycin, Neomethymycin, Novamethymycin, and Ketomethymycin

Douglas Andrew Hansen, Christopher M Rath, Eli Eisman, Alison Narayan, Jeffrey D. Kittendorf, Jonathan David Mortison, Yeo Joon Yoon, and David H. Sherman

*J. Am. Chem. Soc.*, **Just Accepted Manuscript** • DOI: 10.1021/ja404134f • Publication Date (Web): 18 Jun 2013

Downloaded from <http://pubs.acs.org> on June 19, 2013

## Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications  
High quality. High impact.

# Biocatalytic Synthesis of Pikromycin, Methymycin, Neomethymycin, Novamethymycin, and Ketomethymycin

Douglas A. Hansen,<sup>α†</sup> Christopher M. Rath,<sup>†</sup> Eli B. Eisman,<sup>†</sup> Alison R. H. Narayan,<sup>†</sup> Jeffrey D. Kittendorf,<sup>†β</sup> Jonathan D. Mortison,<sup>π†</sup> Yeo Joon Yoon,<sup>°</sup> and David H. Sherman<sup>\*α†π‡</sup>

<sup>α</sup>Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109

<sup>‡</sup>Department of Chemistry, University of Michigan, Ann Arbor, MI 48109

<sup>‡</sup>Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI 48109

<sup>β</sup>Alluvium Biosciences, Ann Arbor, MI 48108

<sup>†</sup>Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109

<sup>°</sup>Division of Nano Sciences, Ewha Womans University, Seoul 120-750, South Korea

## AUTHOR INFORMATION

\*Corresponding Author

[davidhs@umich.edu](mailto:davidhs@umich.edu)


Present Addresses

C.M.R. – Novartis Institute for Biomedical Research, Emeryville, CA 94608

J.D.M. - Harvard University, Cambridge, MA 02138

Keywords: Chemoenzymatic Synthesis, Biocatalysis, Pikromycin, Macrolides, Polyketide Synthase

Graphical Abstract:



## Abstract

A biocatalytic platform that employs the final two monomodular type I polyketide synthases (PKS) of the pikromycin pathway *in vitro* followed by direct appendage of D-desosamine and final C-H oxidation(s) *in vivo* was developed and applied toward the synthesis of a suite of 12- and 14-membered ring macrolide natural products. This methodology delivered both compound classes in thirteen steps (longest linear sequence) from commercially available (*R*)-Roche ester in >10% overall yields.

## Introduction

Biocatalysis offers tremendous potential to complement conventional methods in synthetic chemistry.<sup>1</sup> Traditionally used for discrete chemical reactions, recent chemoenzymatic advances have enabled cascades that streamline synthesis by reducing step counts, increasing yields, and minimizing waste generation.<sup>2-3</sup> While such processes are becoming increasingly prevalent, they are typically employed in the production of relatively simple synthons for starting material or later incorporation into mature molecules. Conversely, the biosynthetic machinery involved in the generation of complex secondary metabolites could theoretically be leveraged at late stages of a synthesis to achieve similar improvement in step counts and overall yields. Specifically, modular type I polyketide synthases (PKSs) are of interest as a single polypeptide chain is capable of performing multiple regio- and stereospecific reactions while stabilizing otherwise labile oligoketide substrates.

Pikromycin (**1**) is a PKS derived macrolide antibiotic belonging to the ketolide subclass, originally isolated in 1950.<sup>4-5</sup> The subsequent discovery of erythromycin A (**2**) and its success as a broad spectrum antibiotic initiated drug discovery efforts through isolation and semi-synthetic modification,<sup>6</sup> with 3<sup>rd</sup> generation macrolides treating front line infections almost sixty years

1  
2  
3 later. Through on-going strain improvement programs, fermentation-derived erythromycin  
4 provides the starting material for a number of clinically relevant antibiotics including 2<sup>nd</sup>  
5  
6 generation clarithromycin, azithromycin and the 3<sup>rd</sup> generation ketolides telithromycin (**4**),  
7  
8 cethromycin, and solithromycin. Despite the availability of erythromycin as a commodity fine-  
9  
10 chemical, rigorous structure activity relationship (SAR) studies of the ketolide class are  
11  
12 constrained by the inherent limitations of semi-synthesis using this complex natural product. For  
13  
14 example, methods to directly remove, add, or modify alkyl groups in the macrolactone ring  
15  
16 remain elusive with current synthetic technology. In contrast, *de novo* production of ketolides  
17  
18 though total synthesis offers the opportunity to explore previously inaccessible chemical space  
19  
20 for discovery of new anti-infective agents.<sup>7-10</sup> At present, this remains a formidable goal as  
21  
22 conventional synthetic approaches understandably suffer from practical limitations, even in the  
23  
24 case of natural macrolides or their simplified macrolactone<sup>11-12</sup> skeletons. Total syntheses have  
25  
26 been previously reported for erythromycin<sup>13-15</sup> and pikromycin,<sup>16</sup> however, the innate complexity  
27  
28 of these compounds requires high step counts, resulting in low overall yields. An underexplored  
29  
30 route to macrolactone scaffolds employs PKS enzymes in a controlled *in vitro* environment.  
31  
32 Development of biocatalytic approaches using modular PKSs has the potential to provide ready  
33  
34 access to natural macrolactones, and increase our functional understanding of these complex  
35  
36 proteins toward creating libraries of novel macrolides in an efficient manner.  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 Bacterial PKS pathways mediate the extension and processing of polyketide chains in a  
47  
48 stepwise stereospecific manner, typically adding two (acetate) to three (propionate) carbon atoms  
49  
50 per module.<sup>17</sup> In the case of propionate extension, methylmalonyl-coenzyme A (MM-CoA, **5**)  
51  
52 serves as a masked enolate of the extender unit. The acyl transferase (AT) domain selects for  
53  
54 methylmalonate and transfers this subunit to the phosphopantetheine (Ppant) arm of the acyl  
55  
56  
57  
58  
59  
60

1  
2  
3 carrier protein (ACP), where the ketosynthase (KS) domain accepts a growing chain elongation  
4 intermediate from the previous module and catalyzes a decarboxylative Claisen condensation  
5 placing the extended chain onto the ACP for reductive tailoring. The ketoreductase (KR),  
6 dehydratase (DH), and enoyl reductase (ER) domains modify the chain at the  $\beta$  position,  
7 (depending on the module and the presence of processing domains), while the terminal  
8 thioesterase domain (TE) catalyzes cyclization of the macrolactone product.<sup>18-21</sup>

9  
10  
11  
12  
13  
14  
15  
16  
17  
18 *Streptomyces venezuelae* ATCC 15439 produces a suite of 12- and 14-membered ring  
19 macrolide antibiotics with late-stage PKS modules (e.g. PikAIII and PikAIV) in the biosynthetic  
20 pathway demonstrating substrate flexibility.<sup>22-23</sup> The unnatural PikAIII-TE fusion protein  
21 produces the 12-membered ring macrolactone 10-deoxymethyonolide (10-dml, **7**) from the *N*-  
22 acetylcysteamine thioester (NAC) (**21**) of the natural Pik pentaketide (**6**). Incubation with both  
23 PikAIII and PikAIV monomodules results in two propionate extensions followed by  
24 macrocyclization to yield the 14-membered ring aglycone narbonolide (nbl, **8**).<sup>24</sup> Although  
25 considerable progress has been made in micro-scale analysis of modular PKS systems using  
26 advanced polyketide chain elongation intermediates,<sup>19,23-24</sup> we were motivated to explore the  
27 possibility of a more efficient and scalable biocatalytic system.

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 From a practical perspective, preparative scale (>1 mmol) biocatalysis by type I modular  
42 PKSs has been impeded by a number of technical challenges including (i) slow loading of  
43 substrate onto the KS (ii) stoichiometric and cost-prohibitive cofactors (iii) the large, fragile  
44 nature of PKS proteins. Accordingly, we sought to address these challenges and develop  
45 multifunctional PKS enzymes as options in the toolbox of synthetic chemistry. Finally, tailoring  
46 of the macrolactones to macrolides was envisioned through whole cell biotransformation to  
47 append D-desosamine and perform C-H oxidation(s) by the PikC monooxygenase (Scheme 2).

## Results

**Synthesis of Pik Pentaketide.** Retrosynthetically, we envisioned disconnection at the enone double bond, simplifying the necessary building blocks to  $\alpha,\beta$  unsaturated ketone **18**, a type II olefin,<sup>25</sup> matched to undergo cross metathesis with type I fragment **19**. Synthesis of enone **18** began with TBS protection of (*R*)-Roche ester (**15**),<sup>26-27</sup> which was subsequently reduced and iodinated to yield **16**. Alkylation with (*S,S*)-pseudoephedrine propionamide,<sup>28</sup> displacement of the auxiliary with *n*-BuLi and RuO<sub>4</sub> oxidation<sup>29</sup> furnished saturated acid **17**. Conversion of **17** to enone **18** was envisioned through oxidation of the corresponding silyl enol ether.<sup>30</sup> Trapping the kinetic enolate of **17** with LDA/TMSCl at -78 °C proved problematic as epimerization was observed through a presumed silyl ketene intermediate. Employment of LHMDS/TMSCl at -78 °C facilitated smooth trapping of the enolate<sup>31</sup> and subsequent IBX oxidation of the crude silyl enol ether yielded compound **18**.<sup>30</sup> This two-step sequence initially demonstrated poor reproducibility but was improved through quenching excess LHMDS/TMSCl with a drop wise addition of acetone prior to an aqueous quench to provide **18** in good yield.<sup>32</sup> Common metathesis conditions were evaluated with 1.5 equivalents of silyl ether **19** and 3 mol% of HG-II,<sup>33</sup> where the highest yields were achieved when the reaction was run neat at 50 °C for 12 hours. Cleavage of the silyl ether with hydrogen fluoride in acetonitrile afforded the unactivated pentaketide **5**. With the desired substrate **20** in hand, we considered alternatives to NAC thioesters in an effort to increase efficiency of loading target KS domains to initiate PKS chain extension.

**Synthesis and Evaluation of Pentaketide Thioesters.** We envisioned four Pik pentaketide substrates of varying reactivity and aqueous solubility for direct PKS loading. NAC **21** was synthesized as described previously,<sup>24</sup> while **22-24** were generated from corresponding disulfides.<sup>34</sup> Activated pentaketides **21-24** were incubated with purified PikAIII-TE, extender unit, and hydride donor under non-optimized conditions (Figure 2). QTOF-LC/MS analysis of 50  $\mu$ L reaction mixtures after one hour revealed significant differences in conversion between aryl thioesters and traditionally employed NAC thioesters. Thiophenol activated **22** showed a 4-fold increase in conversion to 10-dml while **23** and **24** demonstrated 2-fold increases. Furthermore, **22** showed no detectable hydrolysis in the absence of enzyme or in the presence of denatured enzyme, while both **23** and **24** underwent detectable hydrolysis. Compounds **21** and **22** were further analyzed via HPLC calibrated against a 10-dml standard curve providing absolute quantification along the reaction time course. Having demonstrated the superiority of thiophenol-activated pentaketide **22** to the previously employed **21**, attention was turned toward exploring alternatives to superstoichiometric quantities of MM-CoA (**5**) and NADPH as essential co-factors.

**Evaluation of Superstoichiometric Co-Factors.** Replacement of MM-CoA is requisite to attain a practical chemoenzymatic platform due to its cost (>\$1000/25 mg)<sup>35</sup> and poor atom economy. Khosla and coworkers reported methylmalonyl *N*-acetylcysteamine (MM-NAC, **25**) as a surrogate for MM-CoA in the erythromycin pathway (DEBS) albeit at higher concentrations.<sup>36</sup> In our hands, gram scale synthesis of MM-NAC was hindered by difficulties in separation from side-products due to the extreme hydrophilicity of the compound. An alternative two-step route proceeded through compound **27**, a crystalline solid available in a single step from methyl

Meldrum's acid (**26**).<sup>37</sup> Transthioesterification<sup>38</sup> in aqueous sodium bicarbonate followed by acidification with cation exchange resin, washing of the aqueous phase with CH<sub>2</sub>Cl<sub>2</sub> and subsequent lyophilization provided rapid access to decagrams of **25**. The stoichiometric dependence of MM-NAC was examined in a stop point assay after 4 hours with both PikAIII-TE and PikAIII/PikAIV (Figure 3). While enzymatic NADPH recycling was potentially problematic in the presence of electrophilic thioesters, the glucose-6-phosphate/glucose-6-phosphate dehydrogenase system<sup>39</sup> proved sufficiently robust to be employed without modification. Ultimately, NADP<sup>+</sup> could be recycled effectively at 10 mol% relative to pentaketide substrate.

**Semi-Preparative and Preparative PKS catalysis.** Following co-factor optimization, we examined the scalability of the *in vitro* macrolactone-forming PKS reactions. Scale-up of analytical 50  $\mu$ L reactions to semi-preparative 200 mL reactions (0.2 mmol **22**) while maintaining identical concentrations and stoichiometry provided 10-dml (**7**) in 53% yield and acetyl-narbonolide (**28**) in 47% yield, respectively after silica gel chromatography (Figure 4). The observed precipitation of modular PKS proteins during the reaction spurred a final evaluation of conditions, and transitioning from purified protein to crude cell lysate while maintaining identical concentrations and stoichiometry demonstrated modest improvement generating 10-dml in 62% yield or acetyl-narbonolide in 55% yield. Increased enzymatic stability enabled subsequent reactions to be conducted at a four-fold greater concentration while decreasing the stoichiometry of MM-NAC by a factor of two, affording 10-dml in 66% yield or acetyl-narbonolide in 55% yield. With final reaction conditions in hand, preparative-scale catalysis with 0.5 g of Pik pentaketide **22** (1.43 mmol) generated 10-dml in 60% yield, and acetyl-narbonolide in 49% yield.



**Biotransformation of Macrolactones to Macrolides.** As the final step toward targeted macrolides, we evaluated whole cell biocatalysis for introduction of D-desosamine and the final p450-mediated C-H oxidation(s). Engineered variants of *Streptomyces venezuelae* ATCC 15439 designated strains DHS2001<sup>40</sup> and YJ112<sup>41</sup> were assayed for their ability to transform macrolactones to macrolides (Figure 5). Observed variation in levels of bioconversion from culture to culture (normalized by time and based on initial culture inoculation to addition of macrolactone) motivated studies to isolate and evaluate growth phase dependence. Addition of the macrolactone substrate to high OD<sub>600</sub> DHS2001 cultures resulted in fast initial rates, but incomplete conversions. By contrast, addition of macrolactone to pre-log phase cultures of resulted in highest overall conversion to macrolide products. While conversion of 10-dml to methymycins (**11-14**) was undetectable with either strain, this was overcome by addition of acetyl-narbonolide (**28**)<sup>42</sup> to afford >99% conversion to target macrolides over 48 hours. Addition of acetyl-narbonolide to narbonolide biotransformations increased rates and overall conversion (>99%) in a similar manner. Bioconversion of 10-dml with DHS2001 predominately afforded neomethymycin and methymycin, with low levels of novamethymycin isolated as well. *S. venezuelae* strain YJ112 mediated conversion of 10-dml with superior access to higher oxidation states including increased levels of novamethymycin, and enabled discovery of the new macrolide ketomethymycin arising from a presumed dihydroxylation at the C-12 position. Addition of narbonolide to *S. venezuelae* strain YJ112 provided pikromycin in 72% yield.

## Discussion

Modern synthesis of polyketide natural products is routinely enabled by chiral auxiliary methodology that predictably forms C-C bonds in a stereoselective, biomimetic manner. Prominent examples, including Myers alkylation<sup>28,43</sup> and Evans aldol<sup>44</sup> protocols and variants thereof, are commonly employed in constructing these complex secondary metabolites. Indeed, a recent synthesis of narbonolide [ $>19$  steps (longest linear sequence) and  $<3\%$  overall yield]<sup>12</sup> and related macrolactone 6-dEB [22 steps (longest linear sequence) and  $7.8\%$  overall yield]<sup>45</sup> relied heavily on these “practical laboratory emulations of the series of acylation/reduction reactions performed by polyketide synthases.”<sup>46</sup> For example, an aldol reaction with *N*-propionyl-2-oxazolidone and propionaldehyde mimics one round of KS catalyzed propionate extension and KR reduction. In this approach, each new C-C bond formed requires further steps to protect installed functionality, displace the auxiliary, and oxidize or otherwise activate the chain for the next C-C bond construction. The thiophenol activated Pik pentaketide **22** was synthesized in this manner [11 linear steps and  $38\%$  yield], demonstrating the typical strengths ( $>90\%$  yield per operation) and shortcomings (numerous redox and protecting group manipulations) of this approach. PKS catalysis offers an attractive alternative to synthetic emulators, as post C-C bond redox steps are performed on the protein with effective stabilization of labile polyketide chains. Covalent attachment of the chain elongation intermediate to the ACP eliminates the need for protective groups prior to subsequent elongation or cyclization.

Despite the clear potential for synthetic utility and more than two decades of investigation,<sup>47-</sup><sup>48</sup> the development of modular PKS based biocatalytic systems has been hindered by the inherent complexity of PKS enzymes. Initial development was complicated by codependent factors that precluded optimizing individual reaction parameters in a stepwise manner. For example, while sensitive radio-assays have been necessary to compensate for the inefficiency of most *in vitro*

PKS reactions and the micro-scale at which they are conducted, their qualitative readout and low-throughput nature make them unsuitable for screening reaction conditions. Fortunately, increased accessibility to high resolution LC/MS enabled us to avoid use of radioactive substrates and establish basic parameters (Figure 2) from which to proceed.

While evaluation of thioester leaving groups by QTOF-LC/MS illuminated striking improvement in substrate conversion and ultimately enabled the development of simple HPLC assays, initial experiments appeared less than promising. The NAC activated Pik pentaketide **21** is sparingly water soluble despite the polarity imparted by NAC, and substitution to more hydrophobic thiophenol **22** led to a visible dispersion at 1mM concentrations. Fortunately, loss of turbidity could be used to visually track the progress of the reaction, with consumption of starting material rendering a clear solution. The superior conversion of aryl thioesters compared to conventional NAC thioesters suggests that increased reactivity trumps possible KS-Ppant interactions. Of particular note is the apparent preference for the Pik pentaketide substrate to load the KS active site cysteine over the ACP Ppant arm, as concomitant ACP acylation would effectively remove the module from participating in catalysis. In retrospect, observed fidelity in loading the PikAIII KS domain active site cysteine residue is surprising given the demonstrated efficacy of thiophenol thioesters in loading Ppant arms of PCP domains.<sup>49-52</sup> Ultimately, PKS mediated conversion of Pik pentaketide proceeded with modest yield to 10-dml [60% yield, 23% overall from **15**] or acetyl-narbonolide [49% yield, 18% overall from **15**] at preparative scale, generating ~250 mg of either macrolactone.

Chemical glycosylation of both macrolactones with D-desosamine<sup>53-54</sup> and subsequent C-H oxidation through PikC monooxygenase have been described,<sup>55</sup> though complications obtaining and attaching D-desosamine significantly impede this approach. This amino sugar can be

chemically synthesized in nine steps,<sup>54,56</sup> though it is more commonly harvested from degradation of erythromycin A.<sup>57-58</sup> Utilizing D-desosamine acquired from degradation requires a multi-step sequence of protection, activation, glycosylation, and deprotection. Further, glycosylation of hindered secondary alcohols in either macrolactone has been challenging and proceeds with moderate yields.<sup>16,54</sup>

Alternatively, the direct biotransformation of macrolactones to macrolides presents an attractive option in converting 10-dml to methymycins (**11–14**) and narbonolide to pikromycin (**1**).<sup>59</sup> In this approach, the 10-dml and narbonolide macrolactones are natural substrates for the D-desosamine biosynthetic pathway and subsequent PikC oxidation within engineered variants of *S. venezuelae* ATCC 15439. Indeed, strain YJ122 efficiently converted crude narbonolide to pikromycin [72% yield, 13% overall from **15**]. Bioconversion of 10-dml to methymycins proved to be tunable depending on the strain employed, with DHS2001 biotransformation affording primarily monohydroxylated products [combined 66% yield, 15% overall from **15**]. *S. venezuelae* strain YJ112 mediated conversion of 10-dml with increased accessibility to dihydroxylated novamethymycin, and provided access to previously unknown ketomethymycin [combined 71% yield, 16% overall from **15**]. Careful analysis of wild type *S. venezuelae* ATCC 15439 culture revealed production of a compound having an identical mass and retention time to synthetic ketomethymycin, suggesting that this compound is indeed a secondary metabolite made in trace quantities under normal laboratory culture conditions.

## Conclusion

Advances in polyketide chain elongation intermediate activation and optimization of *in vitro* reaction parameters yielded practical type I PKS biocatalysis for scalable *de novo* macrolide

1  
2  
3 production. The flexibility of the Pik pathway enabled divergent generation of either 10-dml or  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
production. The flexibility of the Pik pathway enabled divergent generation of either 10-dml or  
narbonolide and optimized whole cell biotransformations effectively tailored macrolactones to  
macrolides, with *S. venezuelae* strain YJ112 enabling access to ketomethymycin bearing a  
previously unobserved oxidation state at the C-12 position. This platform offers practical entry  
to natural 12- and 14 membered ring macrolides from the Pik pathway, and the potential of this  
system to produce unnatural macrolides will be reported in due course.

## Acknowledgments

This research was supported by Rackham Merit and American Foundation for Pharmaceutical  
Education pre-doctoral fellowships (D.A.H.), the Life Sciences Research Foundation (A.R.H.N),  
and NIH grant GM076477 and the Hans W. Vahlteich Professorship (to D.H.S.).

## Captions

Figure 1. Macrolide antibiotics including ketolide **3**,<sup>60</sup> an intermediate en route to telithromycin. from erythromycin A.

Scheme 1. Retrosynthetic analysis. PikC: P450 catalyzing mono- and dihydroxylation of YC-17 (**9**) and narbomycin (**10**) macrolides. DesI-VIII: D-desosamine biosynthetic pathway catalyzing glycosylation of 10-deoxymethynolide (**7**) and narbonolide (**8**) macrolactones. PikAIII-TE or PikAIII/AIV: PKS modules capable of converting Pik pentaketide (**6**) to macrolactones 10-deoxymethynolide (**7**) or narbonolide (**8**).

Scheme 2. Second generation<sup>24</sup> approach to Pik pentaketide.

Figure 2. Synthesis and evaluation of activated Pik pentaketides. Enzymatic reaction conditions: 1mM Pik pentaketide, 10mM MM-NAC (*vide infra*), 0.5mM NADP<sup>+</sup>, 2.5mM glucose-6-phosphate, 0.5 unit/mL glucose-6-phosphate dehydrogenase, 8mM 2-vinylpyridine, and 1μM purified PikAIII-TE, 1-24 hours. Conversion of **21** and **22** to 10-deoxymethynolide (**7**) was monitored (HPLC) with data represented as mean ± standard deviation. n=3


Figure 3. Synthesis and evaluation of methylmalonyl *N*-acetylcysteamine (MM-NAC, **25**) Enzymatic reaction conditions: 1mM Pik pentaketide **22**, 1-20mM MM-NAC, 0.5mM NADP<sup>+</sup>, 2.5mM glucose-6-phosphate, 0.5 unit/mL glucose-6-phosphate dehydrogenase, 8mM 2-vinylpyridine, and 1μM purified PikAIII-TE or PikAIII/PikAIV, 4 hours. Conversion of pentaketides **21** and **22** to 10-deoxymethynolide (**6**) or narbonolide (**7**) was monitored (HPLC) with data represented as mean ± standard deviation. n=3

Figure 4. Semipreparative and preparative PKS cascade to macrolactones. Enzymatic reaction conditions: 1mM-4mM Pik pentaketide **22**, 10-20 equiv. MM-NAC, 0.1mM NADP<sup>+</sup>, 2.5-10mM glucose-6-phosphate, 0.5-2 unit/mL glucose-6-phosphate dehydrogenase, 1-4μM purified<sup>a</sup> or cell free<sup>b</sup> PikAIII-TE or PikAIII/PikAIV, 4 hours. Narbonolide was acetylated to **28** prior to chromatography to prevent degradation. Yields are calculated from isolated macrolactone after chromatography.


Figure 5. Biotransformation of macrolactones to macrolides. Biotransformation conditions: macrolactone added to 100 mg/L with 2.5 mg/L acetyl-narbonolide (**28**) when culture reached OD<sub>600</sub> 0.1, incubated for 48 hours. methymycin (**12**) : R<sub>1</sub>=OH, R<sub>2</sub>=H, neomethymycin (**11**) : R<sub>1</sub>=H, R<sub>2</sub>=OH, novamethymycin (**14**) : R<sub>1</sub>=OH, R<sub>2</sub>=OH, ketomethymycin (**13**) : R<sub>1</sub>=H, R<sub>2</sub>=O. Yields are calculated as the sum of differentially oxidized macrolides after HPLC purification.

Figures

Figure 1:



Scheme 1:





Scheme 2.




Figure 2.




Figure 3.




Figure 4.





Figure 5.



Associated Content

Supporting Information Available: Full experimental details and spectroscopic data. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

## References

- (1) Bornscheuer, U. T.; Huisman, G. W.; Kazlauskas, R. J.; Lutz, S.; Moore, J. C.; Robins, K. *Nature* **2012**, *485*, 185.
- (2) Li, T.; Liang, J.; Ambrogelly, A.; Brennan, T.; Gloor, G.; Huisman, G.; Lalonde, J.; Lekhal, A.; Mijts, B.; Muley, S.; Newman, L.; Tobin, M.; Wong, G.; Zaks, A.; Zhang, X. *J. Am. Chem. Soc.* **2012**, *134*, 6467.
- (3) Greenberg, W. A.; Varvak, A.; Hanson, S. R.; Wong, K.; Huang, H.; Chen, P.; Burk, M. J. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 5788.
- (4) Brockmann, H.; Henkel, W. *Naturwissenschaften* **1950**, *37*, 138.
- (5) Brockmann, H.; Henkel, W. *Chem. Ber.* **1951**, *84*, 284.
- (6) Katz, L.; Ashley, G. W. *Chem. Rev.* **2005**, *105*, 499.
- (7) Velvadapu, V.; Paul, T.; Wagh, B.; Klepacki, D.; Guvench, O.; MacKerell, A., Jr.; Andrade, R. B. *ACS Med. Chem. Lett.* **2011**, *2*, 68.
- (8) Wagh, B.; Paul, T.; Glassford, I.; DeBrosse, C.; Klepacki, D.; Small, M. C.; MacKerell, A. D.; Andrade, R. B. *ACS Med. Chem. Lett.* **2012**, *3*, 1013.
- (9) Velvadapu, V.; Glassford, I.; Lee, M.; Paul, T.; DeBrosse, C.; Klepacki, D.; Small, M. C.; MacKerell, A. D., Jr.; Andrade, R. B. *ACS Med. Chem. Lett.* **2012**, *3*, 211.
- (10) Velvadapu, V.; Paul, T.; Wagh, B.; Glassford, I.; DeBrosse, C.; Andrade, R. B. *J. Org. Chem.* **2011**, *76*, 7516.
- (11) Gao, X.; Woo, S. K.; Krische, M. J. *J. Am. Chem. Soc.* **2013**, *135*, 4223.
- (12) Xuan, R.; Oh, H.-S.; Lee, Y.; Kang, H.-Y. *J. Org. Chem.* **2008**, *73*, 1456.
- (13) Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Auyeung, B. W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H. J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; Rajanbabu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vasella, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N. C. *J. Am. Chem. Soc.* **1981**, *103*, 3210.
- (14) Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Auyeung, B. W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H. J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; Rajanbabu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vasella, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N. C. *J. Am. Chem. Soc.* **1981**, *103*, 3213.
- (15) Woodward, R. B.; Logusch, E.; Nambiar, K. P.; Sakan, K.; Ward, D. E.; Auyeung, B. W.; Balaram, P.; Browne, L. J.; Card, P. J.; Chen, C. H.; Chenevert, R. B.; Fliri, A.; Frobel, K.; Gais, H. J.; Garratt, D. G.; Hayakawa, K.; Heggie, W.; Hesson, D. P.; Hoppe, D.; Hoppe, I.; Hyatt, J. A.; Ikeda, D.; Jacobi, P. A.; Kim, K. S.; Kobuke, Y.; Kojima, K.; Krowicki, K.; Lee, V. J.; Leutert, T.; Malchenko, S.; Martens, J.; Matthews, R. S.; Ong, B. S.; Press, J. B.; Rajanbabu, T. V.; Rousseau, G.; Sauter, H. M.; Suzuki, M.; Tatsuta, K.; Tolbert, L. M.; Truesdale, E. A.; Uchida, I.; Ueda, Y.; Uyehara, T.; Vasella, A. T.; Vladuchick, W. C.; Wade, P. A.; Williams, R. M.; Wong, H. N. C. *J. Am. Chem. Soc.* **1981**, *103*, 3215.

- (16) Oh, H.-S.; Kang, H.-Y. *J. Org. Chem.* **2012**, *77*, 1125.
- (17) Fischbach, M. A.; Walsh, C. T. *Chem. Rev.* **2006**, *106*, 3468.
- (18) Akey, D. L.; Kittendorf, J. D.; Giraldez, J. W.; Fecik, R. A.; Sherman, D. H.; Smith, J. L. *Nat. Chem. Biol.* **2006**, *2*, 537.
- (19) Aldrich, C. C.; Venkatraman, L.; Sherman, D. H.; Fecik, R. A. *J. Am. Chem. Soc.* **2005**, *127*, 8910.
- (20) Giraldez, J. W.; Akey, D. L.; Kittendorf, J. D.; Sherman, D. H.; Smith, J. L.; Fecik, R. A. *Nat. Chem. Biol.* **2006**, *2*, 531.
- (21) Mortison, J. D.; Sherman, D. H. *J. Org. Chem.* **2010**, *75*, 7041.
- (22) Kittendorf, J. D.; Sherman, D. H. *Bioorg. Med. Chem.* **2009**, *17*, 2137.
- (23) Mortison, J. D.; Kittendorf, J. D.; Sherman, D. H. *J. Am. Chem. Soc.* **2009**, *131*, 15784.
- (24) Aldrich, C. C.; Beck, B. J.; Fecik, R. A.; Sherman, D. H. *J. Am. Chem. Soc.* **2005**, *127*, 8441.
- (25) Chatterjee, A. K.; Choi, T. L.; Sanders, D. P.; Grubbs, R. H. *J. Am. Chem. Soc.* **2003**, *125*, 11360.
- (26) Goodhue, C. T.; Schaeffer, J. R. *Biotechnol. Bioeng.* **1971**, *13*, 203.
- (27) Cohen, N.; Eichel, W. F.; Lopresti, R. J.; Neukom, C.; Saucy, G. *J. Org. Chem.* **1976**, *41*, 3505.
- (28) Myers, A. G.; Yang, B. H.; Chen, H.; McKinsty, L.; Kopecky, D. J.; Gleason, J. L. *J. Am. Chem. Soc.* **1997**, *119*, 6496.
- (29) Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, *46*, 3936.
- (30) Nicolaou, K. C.; Gray, D. L. F.; Montagnon, T.; Harrison, S. T. *Angew. Chem., Int. Ed.* **2002**, *41*, 996.
- (31) Heathcock, C. H.; Buse, C. T.; Kleschick, W. A.; Pirrung, M. C.; Sohn, J. E.; Lampe, J. *J. Org. Chem.* **1980**, *45*, 1066.
- (32) Trace (isopropenyloxy)trimethylsilane appears to have little effect on the subsequent IBX oxidation
- (33) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, *122*, 8168.
- (34) Corey, E. J.; Nicolaou, K. C. *J. Am. Chem. Soc.* **1974**, *96*, 5614.
- (35) Sigma Aldrich #M1762
- (36) Pohl, N. L.; Gokhale, R. S.; Cane, D. E.; Khosla, C. *J. Am. Chem. Soc.* **1998**, *120*, 11206.
- (37) Magdziak, D.; Lalic, G.; Lee, H. M.; Fortner, K. C.; Aloise, A. D.; Shair, M. D. *J. Am. Chem. Soc.* **2005**, *127*, 7284.
- (38) Padmakumar, R.; Gantla, S.; Banerjee, R. *Anal. Biochem.* **1993**, *214*, 318.
- (39) Wong, C. H.; Whitesides, G. M. *J. Am. Chem. Soc.* **1981**, *103*, 4890.
- (40) Jung, W. S.; Lee, S. K.; Hong, J. S. J.; Park, S. R.; Jeong, S. J.; Han, A. R.; Sohng, J. K.; Kim, B. G.; Choi, C. Y.; Sherman, D. H.; Yoon, Y. *J. Appl. Microbiol. Biotechnol.* **2006**, *72*, 763.
- (41) Jung, W. S.; Jeong, S. J.; Park, S. R.; Choi, C. Y.; Park, B. C.; Park, J. W.; Yoon, Y. *J. Appl. Environ. Microbiol.* **2008**, *74*, 1972.
- (42) acetyl-narbolide rapidly accelerates biotransformations (manuscript in preparation)

- (43) Morales, M. R.; Mellem, K. T.; Myers, A. G. *Angew. Chem., Int. Ed.* **2012**, *51*, 4568.
- (44) Evans, D. A.; Bartroli, J.; Shih, T. L. *J. Am. Chem. Soc.* **1981**, *103*, 2127.
- (45) Stang, E. M.; White, M. C. *Nat. Chem.* **2009**, *1*, 547.
- (46) Evans, D. A.; Kim, A. S.; Metternich, R.; Novack, V. J. *J. Am. Chem. Soc.* **1998**, *120*, 5921.
- (47) Caffrey, P.; Bevitt, D. J.; Staunton, J.; Leadlay, P. F. *FEBS Lett.* **1992**, *304*, 225.
- (48) Cortes, J.; Haydock, S. F.; Roberts, G. A.; Bevitt, D. J.; Leadlay, P. F. *Nature* **1990**, *348*, 176.
- (49) Grunewald, J.; Marahiel, M. A. *Microbiol. Mol. Biol. Rev.* **2006**, *70*, 121.
- (50) Sieber, S. A.; Tao, J. H.; Walsh, C. T.; Marahiel, M. A. *Angew. Chem., Int. Ed.* **2004**, *43*, 493.
- (51) Grunewald, J.; Sieber, S. A.; Marahiel, M. A. *Biochemistry* **2004**, *43*, 2915.
- (52) Kopp, F.; Mahlert, C.; Gruenewald, J.; Marahiel, M. A. *J. Am. Chem. Soc.* **2006**, *128*, 16478.
- (53) Oh, H. S.; Kang, H. Y. *J. Org. Chem.* **2012**, *77*, 1125.
- (54) Oh, H.-S.; Xuan, R.; Kang, H.-Y. *Org. Biomol. Chem.* **2009**, *7*, 4458.
- (55) Li, S.; Ouellet, H.; Sherman, D. H.; Podust, L. M. *J. Biol. Chem.* **2009**, *284*, 5723.
- (56) Lee, D.-M.; Lee, H.; Kang, H.-Y. *Bull. Korean Chem. Soc.* **2008**, *29*, 535.
- (57) Li, S.; Chaulagain, M. R.; Knauff, A. R.; Podust, L. M.; Montgomery, J.; Sherman, D. H. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 18463.
- (58) Chen, H.; Yamase, H.; Murakami, K.; Chang, C.-w.; Zhao, L.; Zhao, Z.; Liu, H.-w. *Biochemistry* **2002**, *41*, 9165.
- (59) Venkatraman, L.; Salomon, C. E.; Sherman, D. H.; Fecik, R. A. *J. Org. Chem.* **2006**, *71*, 9853.
- (60) Wei, X.; You, Q. *Org. Process Res. Dev.* **2006**, *10*, 446.